A male adolescent with common variable immunodeficiency developed type I diabetes approximately 1 year after the initiation of immunoglobulin therapy. Immunologic evaluation revealed decreased numbers of T cells and an intrinsic B cell defect in immunoglobulin production. Lymphocytes from the patient failed to generate normal suppressor activity. There were no insulin or islet cell antibodies present in the patient's serum or in the commercial immunoglobulin preparations he received. The panent's HLA phenotype included HLA-DR3 and 4, placing him genetically at high risk for type I diabetes.
|Original language||English (US)|
|Number of pages||6|
|Journal||The Journal of Allergy and Clinical Immunology|
|State||Published - Aug 1989|
ASJC Scopus subject areas
- Immunology and Allergy